Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction: Cerebrovascular pathologies including cerebral amyloid angiopathy (CAA) and blood‐brain barrier (BBB) dysregulation are prominent features in the majority of Alzheimer's disease (AD) cases. Methods: We performed neuropathologic and biochemical studies on a large, neuropathologically confirmed human AD cohort (N = 469). Amounts of endothelial tight junction proteins claudin‐5 (CLDN5) and occludin (OCLN), and major AD‐related molecules (amyloid beta [Aβ40], Aβ42, tau, p‐tau, and apolipoprotein E) in the temporal cortex were assessed by ELISA. Results: Higher levels of soluble tau, insoluble p‐tau, and apolipoprotein E (apoE) were independently correlated with lower levels of endothelial tight junction proteins CLDN5 and OCLN in AD brains. Although high Aβ40 levels, APOE ε4, and male sex were predominantly associated with exacerbated CAA severity, those factors did not influence tight junction protein levels. Discussion: Refining the molecular mechanisms connecting tau, Aβ, and apoE with cerebrovascular pathologies is critical for greater understanding of AD pathogenesis and establishing effective therapeutic interventions for the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“28 32 Therefore, in this study, we biochemically assessed how the amounts of two major tight junction proteins, CLDN5 and OCLN, are correlated with CAA severity and the levels of several AD-related molecules, including A β , tau, p-tau, and apoE in the temporal cortex of a large neuropathologically…”
Self-citationDaneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437 · cited 1×
“10 13 To maintain a sealed environment for the brain, the BBB relies on tight junctions which comprise a number of proteins; among them, claudin-5 (CLDN5) and occludin (OCLN) have been shown to be the key transmembrane proteins that regulate endothelial barrier integrity.”
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 1×
“6,7 Furthermore, the effect of cerebrovascular and amyloid pathologies on cognition is likely additive rather than synergistic.”
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Self-citationApolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220
Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882 · cited 1×
“14 BBB leakage is an early neuropathologic event in the development of white matter hyper-intensities (WMHs), one of the main magnetic resonance imaging (MRI) features of cSVD. 15,16 Of note, BBB dysfunction has also been shown to contribute to the pathogenesis of AD.”
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711 · cited 1×
“3,4 Accumulating evidence has shown that risk factors for the vascular cognitive impairment and dementia (VCID) spectrum such as hypertension, diabetes mellitus, atrial fibrillation, hypercholes-terolemia, and reduced physical activity are associated with increased risk for AD.”
VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown
Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A., & John, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808698106 · Cited by 666
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608
Self-citationEllis, R. J., Olichney, J. M., Thal, L. J., Mirra, S. S., Morris, J. C., Beekly, D., & Heyman, A. (1996) · Neurology · doi:10.1212/wnl.46.6.1592 · Cited by 561
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451 · cited 1×
“17,18 Our previous work has demonstrated that endothelial tight junction proteins, which are key components in maintaining BBB integrity, were specifically reduced in the cortical regions during AD progression.”
Self-citationThal, D. R., Ghebremedhin, E., Orantes, M., & Wiestler, O. D. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.12.1287 · Cited by 384
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324
Self-citationSporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms
Attems, J. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1074-9 · Cited by 242 · cited 1×
“20,21 In CAA, A β 40 predominantly deposits in the smooth muscle cell layers of leptomeningeal/cortical arteries and capillaries, 22–25 which is exacerbated in males and in apolipoprotein E (APOE) ε 4 carriers in AD.”
APOE ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes
Zhao, J., Davis, M. D., Martens, Y. A., Shinohara, M., Graff-Radford, N. R., Younkin, S. G., Wszolek, Z. K., Kanekiyo, T., & Bu, G. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx155 · Cited by 221
Self-citationYamazaki, Y., Shinohara, M., Shinohara, M., Yamazaki, A., Murray, M. E., Liesinger, A. M., Heckman, M. G., Lesser, E. R., Parisi, J. E., Petersen, R. C., et al. (2019) · Brain · doi:10.1093/brain/awz011 · Cited by 202 · cited 7×
“The amount of CLDN5 was determined by enzyme-linked immunosorbent assay (ELISA) as described in our published work 19 with minor modification.”
InfluentialSelf-citationApoε4 disrupts neurovascular regulation and undermines white matter integrity and cognitive function
Koizumi, K., Hattori, Y., Ahn, S. J., Buendia, I., Ciacciarelli, A., Uekawa, K., Wang, G., Hiller, A., Zhao, L., Voss, H. U., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06301-2 · Cited by 179
APOE ε2 is associated with increased tau pathology in primary tauopathy
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Linares, C., Kurti, A., Knight, J. A., Heckman, M. G., Diehl, N. N., Shinohara, M., Martens, Y. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06783-0 · Cited by 139
Self-citationBlood–Brain Barrier Dysfunction as a Hallmark Pathology in Chronic Traumatic Encephalopathy
Doherty, C. P., O’Keefe, E., Wallace, E., Loftus, T., Keaney, J., Kealy, J., Humphries, M. M., Molloy, M. G., Meaney, J. F., Farrell, M., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw036 · Cited by 135
Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease
Shinohara, M., Murray, M. E., Frank, R. D., Shinohara, M., DeTure, M., Yamazaki, Y., Tachibana, M., Atagi, Y., Davis, M. D., Liu, C.-C., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1580-y · Cited by 123
Self-citationBlood-Brain Barrier Leakage and Microvascular Lesions in Cerebral Amyloid Angiopathy
Freeze, W. M., Bacskai, B. J., Frosch, M. P., Jacobs, H. I. L., Backes, W. H., Greenberg, S. M., & van Veluw, S. J. (2019) · Stroke · doi:10.1161/strokeaha.118.023788 · Cited by 85 · cited 2×
“As insoluble A β 42 is positively correlated with OCLN levels, A β may exhibit a protective role in BBB damage by antagonizing the apoE effect.”
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“ApoE has been shown to modulate cerebrovascular tight junction integrity independent of CAA in AD brains [155].”
BackgroundSelf-citationLiu, C.-C., Zhao, J., Fu, Y., Inoue, Y., Ren, Y., Chen, Y., Doss, S. V., Shue, F., Jeevaratnam, S., Bastea, L., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01127-0 · Cited by 168
Self-citationAPOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, C.-C., Murray, M. E., Li, X., Zhao, N., Wang, N., Heckman, M. G., Shue, F., Martens, Y., Li, Y., Raulin, A.-C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9375 · Cited by 108
Self-citationJin, Y., Li, F., Sonoustoun, B., Kondru, N. C., Martens, Y. A., Qiao, W., Heckman, M. G., Ikezu, T. C., Li, Z., Burgess, J. D., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02421-8 · Cited by 69
Self-citationZhao, J., Lu, W., Ren, Y., Fu, Y., Martens, Y. A., Shue, F., Davis, M. D., Wang, X., Chen, K., Li, F., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02361-9 · Cited by 58
Self-citation
Metadata
- Authors
- Liu, C., Yamazaki, Y., Heckman, M. G., Martens, Y. A., Jia, L., Yamazaki, A., Diehl, N. N., Zhao, J., Zhao, N., DeTure, M., Davis, M. D., Felton, L. M., Qiao, W., Li, Y., Li, H., Fu, Y., Wang, N., Wren, M., Aikawa, T., Holm, M., Oue, H., Linares, C., Allen, M., Carrasquillo, M. M., Murray, M. E., Petersen, R. C., Ertekin‐Taner, N., Dickson, D. W., Kanekiyo, T., & Bu, G.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2020-08-22
- Volume
- 16
- Issue
- 10
- Pages
- 1372-1383
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W3081167906
- Cited by
- 58
- References
- 26
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.